Evidence map›Paper›PMID 40990023›Full record

ArticleFrontiers in immunology2025

FCRLs and atypical transcriptional pattern in tumor infiltrating B cells from lung and renal cancer.

Ekaterina A Bryushkova, Evgenii V Shchoka, Daniil K Lukyanov, Marina B Gikalo, Natalya Mushenkova, Konstantin K Laktionov, Alexey M Kazakov, Oybek A Khalmurzaev, Vsevolod B Matveev, Dmitriy M Chudakov and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ekaterina A Bryushkova *Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
Evgenii V Shchoka *Genomics of Adaptive Immunity Department, Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
Daniil K Lukyanov *Institute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
Marina B GikaloInstitute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
Natalya MushenkovaInstitute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
Konstantin K LaktionovFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russia.
Alexey M KazakovFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russia.
Oybek A KhalmurzaevFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russia.
Vsevolod B MatveevFederal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of Russian Federation, Moscow, Russia.
Dmitriy M ChudakovInstitute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.
Ekaterina O SerebrovskayaInstitute of Translational Medicine, Pirogov Russian National Research Medical University, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in high-dimensional flow cytometry and single-cell RNA sequencing (scRNA-seq) have enhanced our understanding of the heterogeneity of tumor-infiltrating B cells (TIBs). Subpopulations of TIBs exhibit diverse, sometimes opposing roles in tumor control, influenced by surface molecule, cytokine, and transcription factor expression. IgA and IgG expression in tumors have shown predictive value in melanoma and KRAS-mutated, but not KRAS wild-type, lung adenocarcinoma (LUAD). To investigate the functional differences between B cells producing these isotypes, we performed bulk transcriptome analysis of tumor-infiltrating surface-IgA+ (sIgA+) and sIgG+ memory B cells in LUAD. In LUAD, sIgA+ B cells overexpressed FCRL4, PDCD1, and RUNX2, suggesting an atypical chronically antigen-stimulated phenotype with features of exhaustion. Public scRNA-seq data revealed FCRL4-expressing TIBs as a distinct cluster with upregulation of genes involved in IFNγ and IFNα responses. sIgG+ B cells from LUAD overexpressed IL5RA, indicating a role for IL-5 in class-switch recombination to IgG. TCGA LUAD cohort analysis showed that the FCRL4/CD20 expression ratio correlates with lower survival, reinforcing FCRL4 as a marker of dysfunctional TIBs. Additionally, in renal cancer, high IGHA1/IGHG1 ratios were linked to worse survival. These findings suggest that the IgA/IgG ratio in tumors reflects not only the TME cytokine environment, but also functional differences in B cell populations, providing insights into their diverse roles in tumor progression.

Indexed as

B-LymphocytesKidney NeoplasmsLung NeoplasmsLymphocytes, Tumor-InfiltratingFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunoglobulin AImmunoglobulin GMaleReceptors, FcTranscriptomeFCRL4 protein, humanImmunoglobulin AImmunoglobulin GReceptors, FcFcRL4lung adenocarcinomaRUNX2surface IgAtumor infiltrating B cells

Identifiers

PMID40990023
PMCPMC12450953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.